PDS Biotechnology Corporation (PDSB)
NASDAQ: PDSB · Real-Time Price · USD
1.000
+0.036 (3.71%)
At close: Oct 8, 2025, 4:00 PM EDT
1.020
+0.020 (2.00%)
Pre-market: Oct 9, 2025, 4:28 AM EDT
PDS Biotechnology Employees
PDS Biotechnology had 24 employees as of December 31, 2024. The number of employees decreased by 1 or -4.00% compared to the previous year.
Employees
24
Change (1Y)
-1
Growth (1Y)
-4.00%
Revenue / Employee
n/a
Profits / Employee
-$1,525,091
Market Cap
47.03M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 24 | -1 | -4.00% |
| Dec 31, 2023 | 25 | -1 | -3.85% |
| Dec 31, 2022 | 26 | 4 | 18.18% |
| Dec 31, 2021 | 22 | 7 | 46.67% |
| Dec 31, 2020 | 15 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PDSB News
- 20 days ago - PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population - GlobeNewsWire
- 5 weeks ago - PDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 6 weeks ago - PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer - GlobeNewsWire
- 2 months ago - PDS Biotechnology Corporation (PDSB) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update - GlobeNewsWire
- 2 months ago - PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results - GlobeNewsWire
- 4 months ago - PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC - GlobeNewsWire